1. Home
  2. UBS vs PRPO Comparison

UBS vs PRPO Comparison

Compare UBS & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UBS Group AG Registered

UBS

UBS Group AG Registered

HOLD

Current Price

$43.21

Market Cap

120.6B

Sector

Finance

ML Signal

HOLD

Logo Precipio Inc.

PRPO

Precipio Inc.

N/A

Current Price

$25.00

Market Cap

32.4M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
UBS
PRPO
Founded
1862
N/A
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
120.6B
32.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UBS
PRPO
Price
$43.21
$25.00
Analyst Decision
Buy
Analyst Count
3
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.9M
14.6K
Earning Date
10-29-2025
11-14-2025
Dividend Yield
1.72%
N/A
EPS Growth
84.33
N/A
EPS
2.21
N/A
Revenue
$48,193,000,000.00
$22,800,000.00
Revenue This Year
$4.87
N/A
Revenue Next Year
$3.54
N/A
P/E Ratio
$18.63
N/A
Revenue Growth
2.09
30.95
52 Week Low
$25.75
$3.90
52 Week High
$43.76
$28.50

Technical Indicators

Market Signals
Indicator
UBS
PRPO
Relative Strength Index (RSI) 77.49 58.24
Support Level $38.33 $23.92
Resistance Level $38.27 $25.62
Average True Range (ATR) 0.54 1.42
MACD 0.55 -0.07
Stochastic Oscillator 91.87 74.25

Price Performance

Historical Comparison
UBS
PRPO

About UBS UBS Group AG Registered

UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: